Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Verizon Wireless - Sarasota Memorial Hospital Converged Health Management (CHM) For Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01829152
Recruitment Status : Unknown
Verified July 2014 by Verizon Wireless.
Recruitment status was:  Active, not recruiting
First Posted : April 11, 2013
Last Update Posted : July 28, 2014
Sponsor:
Information provided by (Responsible Party):
Verizon Wireless

Brief Summary:
The primary objective is to evaluate the impact on heart failure related quality of life when integrating a mobile health system, Verizon Wireless's Converged Health Management (CHM), into a subject's self-management of their heart failure (HF) as well as in the medical management of HF by the subjects' clinical team.

Condition or disease Intervention/treatment Phase
Heart Failure Device: CHM Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Verizon Wireless - Sarasota Memorial Hospital Converged Health Management (CHM) For Heart Failure
Study Start Date : December 2013
Estimated Primary Completion Date : September 2014
Estimated Study Completion Date : October 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: Control
Subjects in the Control Group will receive Heart Failure care as routinely delivered by the SMH HF clinicians according to their standards of care.
Experimental: CHM Intervention Group
The Intervention Group subjects will receive Converged Health Management (CHM) in addition to continuing to receive care as routinely delivered by the SMH HF clinicians.
Device: CHM



Primary Outcome Measures :
  1. Quality of life, as measured by subject response to the Minnesota Living with Heart Failure Questionnaire (MLWHF). [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. To assess the impact of the CHM intervention on the subjects' medication adherence as gathered from the Morisky Medication Adherence questionnaire. [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult (≥ 18 years of age)
  2. A least 1 prior hospitalization within the past 12 months for HF based upon the presence of at least 1 symptom (dyspnea, orthopnea, or edema) AND at least 1 sign (rales, peripheral edema, ascites, or pulmonary vascular congestion on chest radiography)AND treatment with a loop diuretic during the hospital stay OR Symptoms of New York Hospital Association (NYHA) Class 2+ symptoms: dyspnea, fatigue, or chest pain with normal physical activity (class II), less than ordinary activity (class III) or at rest (class IV).

    Information may be provided by subject self-report obtained during the initial screening process and/or by medical record confirmation. Compliance with all eligibility criteria will be confirmed at the initial study visit before subject is presented with the ICF.

  3. Receiving care at the SMH HF Clinic and assessed by the clinic at least twice. (Those who were seen in person on their first visit and then followed-up by telephone thereafter will be considered eligible).
  4. Able to provide contact information for someone who agrees to provide information about the subject if the subject is not available to do so.
  5. Capability of understanding and willingness to comply with the protocol and study requirements, assessed according to the Principal Investigator's judgment.
  6. Ability to understand and willingness to sign a written informed consent document, assessed according to the Principal Investigator's judgment.

Exclusion Criteria:

  1. Decline to participate in the study
  2. Reside in an area with limited to no Verizon Wireless coverage as determined by VZ using the VZ zip code coverage analysis technology.
  3. Scheduled procedure for left ventricular device implantation, or listed for potential cardiac transplant
  4. Current resident of a long-term care or skilled nursing facility
  5. Currently receiving palliative or hospice care
  6. Human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS) based on past medical history or subject self-report
  7. Dialysis-dependent, end-stage renal disease
  8. A concurrent physical condition (including rare or chronic diseases such as sickle cell anemia or cystic fibrosis) or mental health condition (including dementia, schizophrenia, or other mental illness) that in the view of the Principal Investigator would compromise the subject's ability to fulfill the protocol requirements or affect the subject's safety during the study
  9. Are unable or unwilling to comply with the study requirements as instructed including coming to the SMH HF clinic for the 2 study visits.
  10. For subjects in the Intervention Group that are:

    1. Unable or unwilling to return to the SMH clinic to receive their training, devices and study material after signing the informed consent form and being randomized into the Intervention Group;
    2. Unable or unwilling to use the biometric devices and CHM at least one time per day.
  11. Are pregnant or planning to become pregnant during the study.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01829152


Locations
Layout table for location information
United States, Florida
Sarasota Memorial Hospital Heart Failure Clinic
Sarasota, Florida, United States, 34239
Sponsors and Collaborators
Verizon Wireless
Investigators
Layout table for investigator information
Principal Investigator: Kirk Voelker, MD Sarasota Memorial Hospital
Layout table for additonal information
Responsible Party: Verizon Wireless
ClinicalTrials.gov Identifier: NCT01829152    
Other Study ID Numbers: SARHF-0319
First Posted: April 11, 2013    Key Record Dates
Last Update Posted: July 28, 2014
Last Verified: July 2014
Keywords provided by Verizon Wireless:
heart failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases